New research, with the caveat of a relatively short follow-up, adds to encouraging data showing an overall low risk of the development of thyroid cancer associated with glucagon-like peptide 1 ...
Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...
The risk for thyroid cancer within the first year of follow-up was higher with GLP-1 therapy vs. other diabetes drugs. Researchers attributed the higher thyroid cancer risk with GLP-1s to ...
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
A recent JAMA Otolaryngology-Head & Neck Surgery study investigates the risk of incident thyroid cancer among adults diagnosed with type 2 diabetes (T2D) and being treated with either glucagon ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.
Get Instant Summarized Text (Gist) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked to an increased risk of thyroid cancer in the first year of treatment for type 2 diabetes ...
The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...
The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...
However, overall, the absolute risk for thyroid cancer is low. (HealthDay News) — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist ...